FindTrial
Sign In

Nationwide survey of 10mg/kg biweekly bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer in Japan

Nationwide survey of 10mg/kg biweekly bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer in Japan - Nationwide survey of 10mg/kg biweekly bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer in Japan

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041658
Enrollment
Unknown
Registered
2020-09-04
Start date
2018-10-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platinum-resistant ovarian cancer

Interventions

None listed

Sponsors

Japan Society of Gynecologic Oncology
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients who received bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer between November 2013 and December 2018

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
To evaluate the real-world usage, efficacy and safety of 10 mg/kg biweekly bevacizumab for the treatment of platinum-resistant ovarian cancer in Japan—

Countries

Japan

Contacts

Public ContactMasayuki Sekine

Niigata University Graduate School of Medical And Dental Sciences Department of obstetrics and gynecology

masa@med.niigata-u.ac.jp025-227-2320

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026